LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 438

Search options

  1. Article: Spatial and nonspatial Morris maze learning: impaired behavioral flexibility in mice with ectopias located in the prefrontal cortex.

    Hyde, Lynn A / Stavnezer, Amy Jo / Bimonte, Heather A / Sherman, Gordon F / Denenberg, Victor H

    Behavioural brain research

    2002  Volume 133, Issue 2, Page(s) 247–259

    Abstract: ... if this conclusion is accurate. We have created a new nonspatial Morris maze for mice that differs from the spatial ... the spatial version and in utilizing intra-maze cues when learning the nonspatial version of the Morris maze ...

    Abstract About half of BXSB/MpJ-Yaa (BXSB) mice have neocortical ectopias (misplaced clusters of neurons located in layer I of cortex). Previous behavioral studies have suggested that ectopic mice have superior spatial, but equivalent nonspatial, reference memory learning. However, since spatial and nonspatial learning were not assessed in the same apparatus and with the same testing procedure, it is unclear if this conclusion is accurate. We have created a new nonspatial Morris maze for mice that differs from the spatial task only in the type of cues that must be utilized to efficiently locate the platform (intra-maze black/white patterns vs. extra-maze room cues) and does not differ in the level of task complexity or the presence of objects within the maze. Ectopic mice were very good in utilizing extra-maze cues when learning the spatial version and in utilizing intra-maze cues when learning the nonspatial version of the Morris maze, while non-ectopics were not, suggesting that ectopics have superior spatial and nonspatial reference memory. Ectopias in BXSB mice are usually located in prefrontal and/or motor cortex. The prefrontal cortex is involved in behavioral flexibility (e.g. being able to easily switch from using spatial to nonspatial cues). Only ectopic mice with ectopias specifically located in the prefrontal region of cortex demonstrated difficulty switching from using extra-maze to intra-maze cues and vice versa. Thus, the presence of one or more ectopias in the prefrontal region of cortex disrupted one of the normal functions of the prefrontal cortex.
    MeSH term(s) Animals ; Behavior, Animal/physiology ; Choristoma/genetics ; Choristoma/pathology ; Choristoma/physiopathology ; Cues ; Male ; Maze Learning/physiology ; Memory/physiology ; Mice ; Mice, Neurologic Mutants ; Prefrontal Cortex/pathology ; Prefrontal Cortex/physiopathology ; Space Perception/physiology
    Language English
    Publishing date 2002-05-20
    Publishing country Netherlands
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 449927-x
    ISSN 1872-7549 ; 0166-4328
    ISSN (online) 1872-7549
    ISSN 0166-4328
    DOI 10.1016/s0166-4328(02)00022-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The third year.

    Sherman, Morris

    JHEP reports : innovation in hepatology

    2021  Volume 3, Issue 2, Page(s) 100259

    Language English
    Publishing date 2021-03-09
    Publishing country Netherlands
    Document type Editorial
    ISSN 2589-5559
    ISSN (online) 2589-5559
    DOI 10.1016/j.jhepr.2021.100259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Assessing Toxicity in Drug Trials in Liver Disease.

    Sherman, Morris

    Seminars in liver disease

    2021  Volume 41, Issue 3, Page(s) 277–284

    Abstract: Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver ... ...

    Abstract Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.
    MeSH term(s) Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/etiology ; Humans ; Liver ; Liver Diseases/diagnosis ; Pharmaceutical Preparations
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2021-03-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603177-8
    ISSN 1098-8971 ; 0272-8087
    ISSN (online) 1098-8971
    ISSN 0272-8087
    DOI 10.1055/s-0041-1723030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The second volume.

    Sherman, Morris

    JHEP reports : innovation in hepatology

    2020  Volume 2, Issue 2, Page(s) 100095

    Language English
    Publishing date 2020-03-04
    Publishing country Netherlands
    Document type Editorial
    ISSN 2589-5559
    ISSN (online) 2589-5559
    DOI 10.1016/j.jhepr.2020.100095
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reminiscences of a soon-to-be ex-hepatologist.

    Sherman, Morris

    Canadian liver journal

    2020  Volume 3, Issue 4, Page(s) 305–308

    Language English
    Publishing date 2020-11-17
    Publishing country Canada
    Document type Editorial
    ISSN 2561-4444
    ISSN (online) 2561-4444
    DOI 10.3138/canlivj-2020-0021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book: Hepatocellular carcinoma

    Sherman, Morris

    (Clinics in liver disease ; 9,2)

    2005  

    Author's details guest ed. Morris Sherman
    Series title Clinics in liver disease ; 9,2
    Collection
    Language English
    Size XII S., S. 191 - 351 : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT014384382
    ISBN 1-4160-2779-3 ; 978-1-4160-2779-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  7. Article ; Online: Editorial musings.

    Sherman, Morris

    JHEP reports : innovation in hepatology

    2019  Volume 1, Issue 2, Page(s) iv–v

    Language English
    Publishing date 2019-08-05
    Publishing country Netherlands
    Document type Editorial
    ISSN 2589-5559
    ISSN (online) 2589-5559
    DOI 10.1016/j.jhepr.2019.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Design and Endpoints of Clinical Trials, Current and Future.

    Sherman, Morris

    Digestive diseases and sciences

    2019  Volume 64, Issue 4, Page(s) 1050–1057

    Abstract: With the advent of several new systemic agents for the treatment of hepatocellular carcinoma and the prospect of more to come it is expected that many more clinical trials will be undertaken to establish the best treatment paradigm(s). In order to help ... ...

    Abstract With the advent of several new systemic agents for the treatment of hepatocellular carcinoma and the prospect of more to come it is expected that many more clinical trials will be undertaken to establish the best treatment paradigm(s). In order to help develop the most efficient and most relevant clinical trials this review concentrates on endpoints that have been used in the past. Survival is the gold standard. None of the surrogate endpoints correspond completely with survival. In addition, alternative clinical trial designs are presented that may be more efficient than the usual phase I, II, and III clinical trial strategy that has been used in the past.
    MeSH term(s) Biomarkers ; Carcinoma, Hepatocellular/therapy ; Clinical Trials as Topic ; Humans ; Liver Function Tests ; Liver Neoplasms/therapy ; Patient Selection ; Research Design
    Chemical Substances Biomarkers
    Language English
    Publishing date 2019-03-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-019-05541-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Assessing Toxicity in Drug Trials in Liver Disease

    Sherman, Morris

    Seminars in Liver Disease

    2021  Volume 41, Issue 03, Page(s) 277–284

    Abstract: Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver ... ...

    Abstract Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.
    Keywords clinical trials ; drug-induced liver injury ; adverse event
    Language English
    Publishing date 2021-03-08
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 603177-8
    ISSN 1098-8971 ; 0272-8087
    ISSN (online) 1098-8971
    ISSN 0272-8087
    DOI 10.1055/s-0041-1723030
    Database Thieme publisher's database

    More links

    Kategorien

  10. Article ; Online: How to improve HCC surveillance outcomes.

    Sherman, Morris

    JHEP reports : innovation in hepatology

    2019  Volume 1, Issue 6, Page(s) 460–467

    Abstract: Outside of expert centres, surveillance programmes for hepatocellular carcinoma (HCC) are not well executed. There are deficiencies in every stage of the process. Overcoming these obstacles is the most important method for improving surveillance. However, ...

    Abstract Outside of expert centres, surveillance programmes for hepatocellular carcinoma (HCC) are not well executed. There are deficiencies in every stage of the process. Overcoming these obstacles is the most important method for improving surveillance. However, even if these obstacles were overcome, there would still be room for improvement. Assessing who is at risk of developing HCC remains incompletely validated. At present, risk scores have been developed for different causes of liver disease, but scores developed in different parts of the world for the same disease do not always agree. Furthermore, most scores stratify patients by risk but do not examine what level of risk should trigger surveillance. Which surveillance tools to use remains controversial - schemes have been proposed that use biomarkers alone, ultrasound alone, or a combination of both. However, the requisite level of test sensitivity that would be associated with high cure rates has not been defined, so at this point it is not clear whether surveillance requires both ultrasound and biomarkers, or whether the use of biomarkers alone is sufficient. Finally, surveillance should result in the identification of HCC at a very early stage. Diagnosing these lesions is difficult and optimal algorithms for lesions that are atypical on radiology have yet to be developed. Algorithms for the follow-up of abnormal biomarkers in the absence of ultrasound have also not been developed yet.
    Language English
    Publishing date 2019-11-05
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2589-5559
    ISSN (online) 2589-5559
    DOI 10.1016/j.jhepr.2019.10.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top